Artelo Biosciences (ARTL) Operating Expenses (2014 - 2025)
Artelo Biosciences (ARTL) posted quarterly Operating Expenses of $2.8 million for Q4 2025, down 26.92% year-over-year from $3.8 million in Q4 2024, and down 9.81% quarter-over-quarter from $3.1 million in Q3 2025.
Artelo Biosciences (ARTL) Operating Expenses (2014 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Operating Expenses for 12 consecutive years, with $2.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Expenses fell 26.92% year-over-year to $2.8 million; the TTM figure through Dec 2025 stood at $11.4 million (up 12.82% YoY), while the FY2025 annual figure was $11.4 million, up 12.82% from the prior year.
- Operating Expenses fell to $2.8 million in Q4 2025 per ARTL's latest filing, from $3.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $3.8 million in Q4 2024 and bottomed at $1.2 million in Q3 2024.
- Historically, Operating Expenses has averaged $2.6 million across 5 years, with a median of $2.5 million in 2021.
- Annual changes were most pronounced in 2024 — Operating Expenses sank 54.28% — and 2025, when it soared 158.49%.
- Artelo Biosciences' Operating Expenses stood at $2.6 million in 2021, then surged by 36.21% to $3.5 million in 2022, then slipped by 6.79% to $3.2 million in 2023, then advanced by 17.65% to $3.8 million in 2024, then decreased by 26.92% to $2.8 million in 2025.
- Business Quant data shows ARTL's Operating Expenses at $2.8 million in Q4 2025, $3.1 million in Q3 2025, and $3.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Artelo Biosciences | 111,698.23 | -488,301.77 | - | 2.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.79 Mn |
| Sep 30, 2025 | 3.09 Mn |
| Jun 30, 2025 | 3.15 Mn |
| Mar 31, 2025 | 2.38 Mn |
| Dec 31, 2024 | 3.81 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 2.51 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | 3.24 Mn |
| Sep 30, 2023 | 2.61 Mn |
| Jun 30, 2023 | 1.78 Mn |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 3.48 Mn |
| Sep 30, 2022 | 2.39 Mn |
| Jun 30, 2022 | 2.47 Mn |
| Mar 31, 2022 | 1.95 Mn |
| Nov 30, 2021 | 2.55 Mn |
| Aug 31, 2021 | 3.78 Mn |
| May 31, 2021 | 2.25 Mn |
| Feb 28, 2021 | 1.87 Mn |